U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT03871517) titled 'INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE' on March 4.
Brief Summary: China has the largest burden of cerebrovascular disease in the world. About 60% to 80% of which are ischemic stroke. In recent years, stroke has replaced heart disease and tumor diseases as the first cause of death and disability in adult population. The primary purpose of this study is to evaluate the efficacy of indobufen treatment in reducing the risk of a 3-month new stroke (any type of stroke, including ischemic stroke and hemorrhagic stroke) for patients with moderate/severe ischemic stroke is not inferior to aspirin therapy.
Study Type: Int...